Crinetics Pharmaceuticals, Inc. filed a Form 8-K on August 14, 2026, reporting that U.S. HSR Act antitrust waiting period expired on August 12, 2026, and that antitrust approvals in Austria, Germany, and Australia were received as of August 13, 2026, in connection with the previously announced merger with Vertex Pharmaceuticals Incorporated.

Key Highlights

  • HSR Waiting Period Expired: The U.S. Hart-Scott-Rodino antitrust waiting period expired at 12:45 p.m. Eastern Time on August 12, 2026.
  • Foreign Approvals Received: Antitrust approvals required in Austria, Germany, and Australia were received as of August 13, 2026.
  • Australian Waiting Period Pending: An Australian waiting period remains scheduled to expire on August 27, 2026 at 9:59 a.m. Eastern Time.
  • Shareholder Vote Scheduled: A special meeting of Crinetics shareholders is scheduled for August 28, 2026, to vote on adoption of the merger.
  • Expected Closing: Assuming shareholder adoption at the August 28, 2026 meeting, the merger and related transactions are expected to close in early September 2026.
  • Merger Structure: Clark Merger Sub, Inc., a wholly owned subsidiary of Vertex, will merge with and into Crinetics, with Crinetics surviving as a wholly owned subsidiary of Vertex.

Crinetics Pharmaceuticals Antitrust Clearances and Merger Timeline Update

According to the filing, Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) entered into an Agreement and Plan of Merger on July 6, 2026, with Vertex Pharmaceuticals Incorporated and Clark Merger Sub, Inc., a wholly owned subsidiary of Vertex. Under the agreement, Merger Sub will be merged with and into Crinetics, with Crinetics surviving the merger as a wholly owned subsidiary of Vertex.

The filing discloses that two significant antitrust conditions have now been satisfied. The waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 expired at 12:45 p.m. Eastern Time on August 12, 2026. Additionally, as of August 13, 2026, the company disclosed that approvals required under applicable antitrust laws in Austria, Germany, and Australia were received, subject to a remaining Australian waiting period currently scheduled to expire on August 27, 2026 at 9:59 a.m. Eastern Time.

The filing notes that the merger remains subject to other closing conditions, including adoption of the merger by Crinetics' shareholders at a special meeting scheduled for August 28, 2026. The filing states that, assuming shareholder adoption at that meeting, the merger and related transactions "are expected to close in early September 2026." The filing includes forward-looking statements that the company identified as subject to risks and uncertainties, and Crinetics stated it "disclaims any obligation to update the information" except as required by law.

What Was Disclosed

Crinetics reported the expiration of the U.S. HSR antitrust waiting period on August 12, 2026, and receipt of required antitrust clearances in Austria, Germany, and Australia as of August 13, 2026, with a shareholder vote on the Vertex merger set for August 28, 2026.